FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First

Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.

More from Archive

More from Pink Sheet